Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Akero Therapeutics

Request full access

Innovative therapies targeting metabolic liver disease

Cambridge, United StatesFounded 2017Biotech & Life Sciences

About Akero Therapeutics

Akero Therapeutics is a biopharmaceutical company focused on developing innovative treatments for non-alcoholic steatohepatitis (NASH), a severe liver disease affecting millions globally. The company's lead product, AKR-001, is designed to address NASH holistically by reducing liver fat, inflammation, and fibrosis, while also improving lipoprotein profiles to lower cardiovascular risks. Akero operates in the healthcare and pharmaceutical market, targeting patients with NASH and related metabolic disorders. The business model revolves around research and development of therapeutic candidates, progressing through clinical trials, and eventually seeking regulatory approval for commercialization. Revenue is generated through partnerships, licensing agreements, and future product sales.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

Akero Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Akero Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

20 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A11 investors entered at this stage

Series B and later9 investors entered at this stage

Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$130k

4 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Akero Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.